PRESCIENT THERAPEUTICS LTD(PTX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

PTX.AU PRESCIENT THERAPEUTICS LTD

Market Closed 05-22 16:12:00 AEST

0.08

+0.01

+13.89%

High0.08	Low0.07	Vol2.10M
Open0.07	D1 Closing0.07	Amplitude15.28%
Mkt Cap86.22M	Tradable Cap70.82M	Total Shares1.05B
T/O161.94K	T/O Rate0.24%	Tradable Shares863.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PTX.AU","market":"AU","secType":"STK","nameCN":"PRESCIENT THERAPEUTICS LTD","latestPrice":0.082,"timestamp":1779430320000,"preClose":0.072,"halted":0,"volume":2102441,"delay":0,"changeRate":0.13888888888888903,"nameEN":"PRESCIENT THERAPEUTICS LTD","floatShares":863697911,"shares":1051514543,"eps":-0.00987,"marketStatus":"Market Closed","change":0.01,"latestTime":"05-22 16:12:00 AEST","open":0.072,"high":0.082,"low":0.071,"amount":161936,"amplitude":0.152778,"askPrice":0.082,"askSize":94212,"bidPrice":0.081,"bidSize":50000,"shortable":3,"etf":0,"ttmEps":-0.00987,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1779667200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.072,"openAndCloseTimeList":[[1779408000000,1779429600000]],"volumeRatio":2.051855779064703,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PTX.AU","preClose":0.072,"auctionPrice":0.082,"auctionVolume":69000,"auction":3,"marketStatus":"盘后竞价","timestamp":1779430200583}},"requestUrl":"/m/hq/s/PTX.AU/tweets","defaultTab":"tweets","newsList":[{"id":"2631573689","title":"Prescient Therapeutics Ltd-March 2026 Quarterly Update and Appendix 4C","url":"https://stock-news.laohu8.com/highlight/detail?id=2631573689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631573689?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:25","pubTimestamp":1777505110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUEYQZHM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591691830","title":"Prescient Therapeutics Secures European Authorization to Start Clinical Trial in Italy; Shares Hit Two-Year High","url":"https://stock-news.laohu8.com/highlight/detail?id=2591691830","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591691830?lang=en_us&edition=fundamental","pubTime":"2025-12-15 11:06","pubTimestamp":1765767988,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics (ASX:PTX) secured authorization from the European Clinical Trials Information System to begin its clinical trial for cancer drug candidate PTX-100 in patients with relapsed/refr","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK7067","PTX.AU","BK4007","BK7508","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591869306","title":"BRIEF-Prescient Therapeutics Secures EU Authorisation To Commence PTX-100 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591869306","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591869306?lang=en_us&edition=fundamental","pubTime":"2025-12-15 09:24","pubTimestamp":1765761878,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics Secures EU Authorisation To Commence PTX-100 Clinical TrialDec 15 (Reuters) - Prescient Therapeutics Ltd PTX.AX:SECURES EU AUTHORISATION TO COMMENCE PTX-100 CLINICAL TRIALFurther company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XJ00D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591698706","title":"BUZZ-Australia's Prescient Therapeutics hits two-year high on EU nod for cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2591698706","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591698706?lang=en_us&edition=fundamental","pubTime":"2025-12-15 08:56","pubTimestamp":1765760176,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Prescient Therapeutics hits two-year high on EU nod for cancer therapy** Shares of Australia's Prescient Therapeutics PTX.AX rise as much as 11.2% to A$0.099, their highest since earl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL01Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591662031","title":"Prescient Therapeutics - Secures EU Authorisation to Commence Ptx-100 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591662031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591662031?lang=en_us&edition=fundamental","pubTime":"2025-12-15 06:11","pubTimestamp":1765750266,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251214:nFWN3XJ00D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584960552","title":"BUZZ-Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2584960552","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584960552?lang=en_us&edition=fundamental","pubTime":"2025-11-19 08:41","pubTimestamp":1763512912,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy** Shares of Prescient Therapeutics PTX.AX rise as much as 29.2% to A$0.062, their highest level since December 23, 2024** Clinical-stage oncology company heading for best day since December 2024, if gains hold** Co says European Medicines Agency grants orphan drug designation to PTX-100 for treating cutaneous T-cell lymphoma** About 4.4 million shares change hand, 3.9x 30-day average** Stock up 10% this year, including the day's move  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL6N3WV00V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTX.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584969925","title":"BRIEF-Prescient Therapeutics Secures EU Orphan Drug Designation For PTX-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2584969925","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584969925?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:04","pubTimestamp":1763503448,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics Secures EU Orphan Drug Designation For PTX-100Nov 19 (Reuters) - Prescient Therapeutics Ltd PTX.AX:PTX SECURES EU ORPHAN DRUG DESIGNATION FOR PTX-100 IN CTCLFurther company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUE6THPBP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTX.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584296999","title":"Prescient Therapeutics Ltd-Ptx Secures EU Orphan Drug Designation for Ptx-100 in Ctcl","url":"https://stock-news.laohu8.com/highlight/detail?id=2584296999","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584296999?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:02","pubTimestamp":1763503360,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUE6THPBP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PTX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ptxtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.2615},{"period":"1month","weight":0.3898},{"period":"3month","weight":0.2239},{"period":"6month","weight":0.5185},{"period":"1year","weight":0.7447},{"period":"ytd","weight":-0.0238}],"compareEarnings":[{"period":"1week","weight":0.0331},{"period":"1month","weight":0.002},{"period":"3month","weight":-0.019},{"period":"6month","weight":0.0463},{"period":"1year","weight":0.1094},{"period":"ytd","weight":0.0021}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. It has a collaboration agreement with Carina Biotech to develop next generation cellular therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.393939,"avgChangeRate":-0.012567},{"month":2,"riseRate":0.3125,"avgChangeRate":-0.006341},{"month":3,"riseRate":0.3125,"avgChangeRate":0.002769},{"month":4,"riseRate":0.28125,"avgChangeRate":-0.054506},{"month":5,"riseRate":0.225806,"avgChangeRate":-0.023664},{"month":6,"riseRate":0.645161,"avgChangeRate":0.059027},{"month":7,"riseRate":0.354839,"avgChangeRate":0.013698},{"month":8,"riseRate":0.354839,"avgChangeRate":-0.009676},{"month":9,"riseRate":0.4375,"avgChangeRate":0.010687},{"month":10,"riseRate":0.4375,"avgChangeRate":0.178691},{"month":11,"riseRate":0.40625,"avgChangeRate":0.026438},{"month":12,"riseRate":0.46875,"avgChangeRate":0.04673}],"exchange":"ASX","name":"PRESCIENT THERAPEUTICS LTD","nameEN":"PRESCIENT THERAPEUTICS LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PRESCIENT THERAPEUTICS LTD(PTX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest PRESCIENT THERAPEUTICS LTD(PTX.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"PRESCIENT THERAPEUTICS LTD,PTX.AU,PRESCIENT THERAPEUTICS LTD股票,PRESCIENT THERAPEUTICS LTD股票老虎,PRESCIENT THERAPEUTICS LTD股票老虎国际,PRESCIENT THERAPEUTICS LTD行情,PRESCIENT THERAPEUTICS LTD股票行情,PRESCIENT THERAPEUTICS LTD股价,PRESCIENT THERAPEUTICS LTD股市,PRESCIENT THERAPEUTICS LTD股票价格,PRESCIENT THERAPEUTICS LTD股票交易,PRESCIENT THERAPEUTICS LTD股票购买,PRESCIENT THERAPEUTICS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PRESCIENT THERAPEUTICS LTD(PTX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest PRESCIENT THERAPEUTICS LTD(PTX.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}